

CLAIMS

1. The use of a GABA_B receptor antagonist for increasing neurotrophin levels in the CNS.
2. The use of a GABA_B receptor antagonist for the treatment of a condition responsive to an increase of neurotrophin levels in the CNS.
3. The use of a GABA_B receptor antagonist for the treatment of neurodegeneration.
4. The use of a GABA_B receptor antagonist for the treatment of Parkinson's disease, amyotrophic lateral sclerosis and stress-induced neurodegeneration.
5. The use of a GABA_B receptor antagonist for suppression of immune responses following CNS tissue grafts.
6. The use of a GABA_B receptor antagonist for the manufacture of a pharmaceutical composition responsive to an increase of neurotrophin levels in the CNS.
7. The use according to any one of claims 1 to 6 for increasing NGF and BDNF.
8. A pharmaceutical composition comprising a GABA_B receptor antagonist in association with at least one pharmaceutical carrier or diluent, for use in the treatment of a condition responsive to an increase of neurotrophin levels in the CNS.
9. A method for increasing neurotrophin levels in the CNS of a subject in need of such treatment, which comprises administering to said subject a therapeutically effective amount of a GABA_B receptor antagonist.
10. A method for treating a condition responsive to an increase of neurotrophin levels in the CNS, in a subject in need of such treatment, which comprises administering to said subject a therapeutically effective amount of a GABA_B receptor antagonist.

11. A method for treating neurodegeneration or for suppression of immune responses following CNS tissue grafts in a subject in need of such treatment, which comprises administering to said subject a therapeutically effective amount of a GABA_B receptor antagonist.

09/06/2014 09:10:01
"09/06/2014 09:10:01"